Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China
- PMID: 12679912
- PMCID: PMC4611430
- DOI: 10.3748/wjg.v9.i4.692
Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China
Abstract
Aim: One of the characteristics of hepatocellular carcinoma (HCC) in Qidong area is the selective mutation resulting in a serine substitution at codon 249 of the p53 gene (1, 20), and it has been identified as a "hotspot" mutation in heptocellular carcinomas occurring in populations exposed to aflatoxin and with high prevalence of hepatitis B virus carriers (2,3,9, 10,16,24). We evaluated in this paper whether this "hotspot" mutation could be detected in cell-free DNA circulating in plasma of patients with hepatocellular carcinoma and cirrhosis in Qidong, China, and tried to illustrate the significance of the detection of this molecular biomarker.
Methods: We collected blood samples from 25 hepatocellular carcinoma patients, 20 cirrhotic patients and 30 healthy controls in Qidong area. DNA was extracted and purified from 200 microl of plasma from each sample. The 249(Ser) p53 mutation was detected by restriction digestion analysis and direct sequencing of exon-7 PCR products.
Results: We found in exon 7 of p53 gene G-T transversion at the third base of codon 249 resulting 249(Arg) - 249(Ser) mutation in 10/25 (40 %) hepatocellular carcinoma cases, 4/20 (20 %) cirrhotics, and 2/30 (7 %) healthy controls. The adjusted odds ratio for having the mutation was 22.1(95 % CI, 3.2-91.7) for HCC cases compared to controls.
Conclusion: These data show that the 249(Ser) p53 mutation in plasma is strongly associated with hepatocellular carcinoma in Qidong patients. We found this mutation was also detected, although it was at a much lower frequency, in plasma DNA of Qidong cirrhotics and healthy controls; We consider that these findings, together with the usual method of HCC diagnosis, will give more information in early diagnosis of HCC, and 249(Ser) p53 mutation should be developed to a new early diagnostic marker for HCC.
Figures



Similar articles
-
Plasma 249Ser p53 mutation in patients with hepatocellular carcinoma residing in a high risk area.J Cell Mol Med. 2003 Jan-Mar;7(1):89-92. doi: 10.1111/j.1582-4934.2003.tb00207.x. J Cell Mol Med. 2003. PMID: 12767266 Free PMC article.
-
P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.Cancer. 2000 Apr 1;88(7):1565-73. doi: 10.1002/(sici)1097-0142(20000401)88:7<1565::aid-cncr10>3.0.co;2-9. Cancer. 2000. PMID: 10738214
-
Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia.J Natl Cancer Inst. 2000 Jan 19;92(2):148-53. doi: 10.1093/jnci/92.2.148. J Natl Cancer Inst. 2000. PMID: 10639517
-
Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma.Ann Acad Med Singap. 1996 Jan;25(1):22-30. Ann Acad Med Singap. 1996. PMID: 8779541 Review.
-
p53 gene in hepatocellular carcinomas from Australia.Cancer Detect Prev. 1994;18(2):123-30. Cancer Detect Prev. 1994. PMID: 8025894 Review.
Cited by
-
Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.Mol Cancer. 2019 Jul 3;18(1):114. doi: 10.1186/s12943-019-1043-x. Mol Cancer. 2019. PMID: 31269959 Free PMC article. Review.
-
Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.Int J Mol Sci. 2021 Jul 10;22(14):7411. doi: 10.3390/ijms22147411. Int J Mol Sci. 2021. PMID: 34299031 Free PMC article.
-
Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.J Zhejiang Univ Sci B. 2007 Feb;8(2):81-7. doi: 10.1631/jzus.2007.B0081. J Zhejiang Univ Sci B. 2007. PMID: 17266182 Free PMC article.
-
Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.Cancer Prev Res (Phila). 2018 Feb;11(2):103-112. doi: 10.1158/1940-6207.CAPR-17-0235. Epub 2017 Oct 31. Cancer Prev Res (Phila). 2018. PMID: 29089331 Free PMC article.
-
Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis.Eur J Cancer. 2012 Sep;48(14):2125-36. doi: 10.1016/j.ejca.2012.02.009. Epub 2012 Mar 8. Eur J Cancer. 2012. PMID: 22405700 Free PMC article.
References
-
- Jackson PE, Groopman JD. Aflatoxin and liver cancer. Baillieres Best Pract Res Clin Gastroenterol. 1999;13:545–555. - PubMed
-
- Hsia CC, Kleiner DE, Axiotis CA, Di Bisceglie A, Nomura AM, Stemmermann GN, Tabor E. Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. J Natl Cancer Inst. 1992;84:1638–1641. - PubMed
-
- Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, Tsai WY, Santella RM. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 1997;57:3471–3477. - PubMed
-
- Park US, Su JJ, Ban KC, Qin L, Lee EH, Lee YI. Mutations in the p53 tumor suppressor gene in tree shrew hepatocellular carcinoma associated with hepatitis B virus infection and intake of aflatoxin B1. Gene. 2000;251:73–80. - PubMed
-
- Lee YI, Lee S, Das GC, Park US, Park SM, Lee YI. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene. 2000;19:3717–3726. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous